Android Apple

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

By Yahoo! Finance   |   2 months ago
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

BofA Securities upgraded Tyra Biosciences, a biotech company focusing on precision medicines. Tyra-300 showed promising preclinical results in hypochondroplasia. BofA raised the stock rating to Buy with a $31 price target ahead of TYRA-300's presentation.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.